OKYO Pharma Ltd - OKYO Net earnings per one share for the last twelve months

OKYO Pharma Limited (OKYO) - corporate logo

Historical price action on the GURU.Markets platform demonstrates the -39.10 metric, while the business relies on the expertise of Gary Jacob and his team, who skillfully manage costs and investor confidence. Costly trials and patent protection for application methods create a high barrier to entry. Ultimately, the success of OKYO Pharma Limited (OKYO) in combating dry eye depends on the confirmed efficacy of the OK-101 molecule.

OKYO OKYO Pharma Inc: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

Financial and market metric breakdowns for OKYO Pharma Inc (OKYO)

- issuer market value details:
Initial company analysis:OKYO, OKYO Pharma Limited
Mass-produced product of OKYO Pharma Ltd

This indicator measures the earnings per share (EPS) dynamics over a rolling year, reflecting the efficiency of business capitalization and net income growth rates relative to previous periods. By analyzing the EPS YoY TTM growth value, an investor assesses the ability of OKYO Pharma Limited (OKYO) to convert clinical trial successes and FDA regulatory approvals into actual financial results, which is critical for valuing the company ahead of potential M&A transactions.

Direct competitors

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|Net earnings per share for the last 12 months KALA|IRD - Net earnings per share for the trailing year|Net earnings per share for the last 12 months ADVM (adverum.com)|OTLK - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters